Bausch Health Companies Inc.
TSX:BHC.TO · Toronto Stock Exchange
-$0.08 today
Vol 0.32M · Avg 0.42M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-28.9%
avg 43.9%
ROIC
3.2%
avg 0.8%
ROA
0.6%
avg -2.5%
Analysis
ROIC is currently the strongest return metric at 3.2% versus its period average of 0.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Thomas J. Appio | Chief Executive Officer & Director | $5.38M | — | 64 | — | — |
Jean-Jacques Charhon | Executive Vice President & Chief Financial Officer | $1.94M | — | 61 | — | — |
Seana Carson | Executive Vice President & General Counsel | $1.86M | — | 53 | — | — |
Aimee J. Lenar | Executive Vice President of US Pharma | $1.82M | — | 50 | — | — |
Jonathan Sadeh | Executive Vice President, Chief Medical Officer and Head of R&D | — | — | — | — | — |
Cees Heiman | Senior Vice President of Europe & Canada | — | — | — | — | — |
Garen Sarafian | Vice President & Head of Investor Relations | — | — | — | — | — |
Steven Lee | Senior Vice President, Controller & Chief Accounting Officer | — | — | 55 | — | — |
Jiny Kim | Senior Vice President of Solta Medical | — | — | 48 | — | — |
Mirza Dautbegovic | Executive Vice President & Chief Operating Officer | — | — | — | — | — |
Kathleen Fitzpatrick | Executive Vice President and Chief HR & Communications Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +43.6% | -0.7% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | +169.2% | +0.4% (15yr)3 analysts |
Analysis
Recent growth has been strongest in EBIT at +169.2% over three years. Forward estimates point to EBIT at +0.4% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Curaleaf Holdings, Inc.
TSX:CURA.TO
$3.18B
Trulieve Cannabis Corp.
TRUL.CN
$2.74B
Green Thumb Industries Inc.
GTII.CN
$2.46B
Cronos Group Inc.
TSX:CRON.TO
$1.40B
Tilray Brands, Inc.
TSX:TLRY.TO
$784.60M
Verano Holdings Corp.
VRNO.NE
$583.95M
Cipher Pharmaceuticals Inc.
TSX:CPH.TO
$408.04M
BioSyent Inc.
RX.V
$160.14M
Grown Rogue International Inc.
GRIN.CN
$149.96M
1CM Inc.
EPIC.CN
$15.89M
Who manages BHC.TO?
Bausch Health Companies Inc. (BHC.TO) lists 11 active executives. The top listed executive is Jonathan Sadeh, Executive Vice President, Chief Medical Officer and Head of R&D.
Explore More
Continue the stock analysis
Jump to another research area for this company.